HEALTHPEAK PROPERTIES, INC. 8-K

What Happened

• On March 23, 2026, Healthpeak Properties, Inc. (through Healthpeak OP and related subsidiaries) filed an 8‑K announcing amendments to three credit agreements and the creation of a new incremental delayed‑draw term loan facility in connection with the completion of Janus Living, Inc.’s IPO.
• The company obtained a $400.0 million senior unsecured delayed‑draw term loan commitment (the Incremental DDTL Facility) with a five‑year stated maturity; lenders’ consent to the Janus IPO and related transactions was also documented.

Key Details

• Amendment date: March 23, 2026 (Closing Date). Parties include Healthpeak, Healthpeak OP, DOC DR Holdco/ DOC DR and lending syndicates (Bank of America N.A. and KeyBank as administrative agents).
• Incremental DDTL Facility: $400.0 million senior unsecured delayed‑draw term loan, five‑year maturity; interest = margin + (borrower’s choice of base rate, Term SOFR or Daily SOFR). Initial margins based on current ratings: 0.00% for base rate loans (floor 1.00%) and 0.80% for Term SOFR/Daily SOFR loans (SOFR floor 0.00%). Overall margin ranges: 0.00%–0.55% (base) and 0.70%–1.55% (SOFR).
• Term loan capacity increase: Maximum aggregate borrowing capacity under the Healthpeak Term Loan Credit Agreement increased from $1.5 billion to $2.0 billion (an Incremental Increase). After giving effect to the amendment, unused borrowing capacity was $750.0 million.
• Guarantees and terms: The Incremental DDTL Facility is guaranteed by Healthpeak, DOC Holdco and DOC DR, and is subject to customary affirmative/negative covenants, reporting requirements and events of default consistent with the amended term loan agreement. Revolving and Physicians‑Realty term loan amendments provided lender consent to the IPO but did not change maturity, pricing or outstanding commitments.

Why It Matters

• This filing creates a new, material borrowing capacity (a $400M delayed‑draw loan) and raises total term‑loan capacity to $2.0B, which improves Healthpeak OP’s optional liquidity sources and flexibility to fund operations or strategic needs.
• The initial low margins (including a 0.00% base margin at current ratings) and multiple rate options may keep borrowing costs competitive, but the facility remains subject to standard covenants and guarantees that investors should monitor.
• The amendments also document lender consent to the Janus Living IPO, removing a potential covenant/permitted‑transaction concern without changing the company’s revolving or other term‑loan economics.